# Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients

> **NCT01641536** · PHASE1 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **GENETIC:** HB-110

## Key facts

- **NCT ID:** NCT01641536
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-12
- **Final completion:** 2013-04
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641536, "Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01641536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*